These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 16891293

  • 1. Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure.
    Hennekens CH, Kowalczykowski M, Hollar D.
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):149-52. PubMed ID: 16891293
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators.
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
    [Abstract] [Full Text] [Related]

  • 4. [Angiotensin receptor blockers in heart failure. CHARM Study].
    Kochsiek K.
    Internist (Berl); 2004 Sep; 45(9):1063-7. PubMed ID: 15309315
    [No Abstract] [Full Text] [Related]

  • 5. [CHARM study--new strategy for the treatment of heart failure].
    Hasegawa H, Komuro I.
    Nihon Rinsho; 2004 May; 62(5):995-1002. PubMed ID: 15148833
    [Abstract] [Full Text] [Related]

  • 6. The CHARM program: study design leads to findings of clinical and public health importance.
    Hennekens CH, Pfeffer MA, Swedberg K.
    J Cardiovasc Pharmacol Ther; 2007 Jun; 12(2):124-6. PubMed ID: 17562782
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB.
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA, CHARM Investigators.
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [Abstract] [Full Text] [Related]

  • 9. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 10. Exploring new treatment strategies in heart failure.
    Swedberg K.
    Blood Press Suppl; 2000 Oct 20; 1():44-8. PubMed ID: 11059637
    [Abstract] [Full Text] [Related]

  • 11. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
    Erhardt LR.
    Int J Clin Pract; 2005 May 20; 59(5):571-8. PubMed ID: 15857354
    [Abstract] [Full Text] [Related]

  • 12. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
    Jneid H, Moukarbel GV, Dawson B, Hajjar RJ, Francis GS.
    Am J Med; 2007 Dec 20; 120(12):1090.e1-8. PubMed ID: 18060931
    [Abstract] [Full Text] [Related]

  • 13. Initial data supporting the design of the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    McKelvie RS.
    J Hypertens Suppl; 2006 Mar 20; 24(1):S9-13. PubMed ID: 16601580
    [Abstract] [Full Text] [Related]

  • 14. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

  • 15. [AT1 blockers against heart failure. The charm of polypharmacy].
    MMW Fortschr Med; 2003 Sep 18; 145(38):6. PubMed ID: 14603670
    [No Abstract] [Full Text] [Related]

  • 16. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators.
    N Engl J Med; 2001 Dec 06; 345(23):1667-75. PubMed ID: 11759645
    [Abstract] [Full Text] [Related]

  • 17. Valsartan in chronic heart failure.
    Ripley TL.
    Ann Pharmacother; 2005 Mar 06; 39(3):460-9. PubMed ID: 15687480
    [Abstract] [Full Text] [Related]

  • 18. [Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
    Kudo Y, Komuro I, Akazawa H.
    Nihon Rinsho; 2007 May 28; 65 Suppl 5():84-9. PubMed ID: 17571370
    [No Abstract] [Full Text] [Related]

  • 19. Alpha-1 adrenoceptor-angiotensin II type 1 receptor cross-talk and its relevance in clinical medicine.
    Vittorio TJ, Fudim M, Wagman G, Kosmas CE.
    Cardiol Rev; 2014 May 28; 22(2):51-5. PubMed ID: 23707993
    [Abstract] [Full Text] [Related]

  • 20. [Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
    Rakugi H, Ogihara T.
    Nihon Rinsho; 2001 Oct 28; 59(10):2051-61. PubMed ID: 11676153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.